231 related articles for article (PubMed ID: 31162800)
1. The Labyrinth of Product Development and Regulatory Approvals in Liquid Biopsy Diagnostics.
Goodsaid FM
Clin Transl Sci; 2019 Sep; 12(5):431-439. PubMed ID: 31162800
[TBL] [Abstract][Full Text] [Related]
2. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
Tazawa Y
Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
[TBL] [Abstract][Full Text] [Related]
3. Companion diagnostics: a regulatory perspective from the last 5 years of molecular companion diagnostic approvals.
Roscoe DM; Hu YF; Philip R
Expert Rev Mol Diagn; 2015; 15(7):869-80. PubMed ID: 26109316
[TBL] [Abstract][Full Text] [Related]
4. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics.
Senderowicz AM; Pfaff O
Clin Cancer Res; 2014 Mar; 20(6):1445-52. PubMed ID: 24634467
[TBL] [Abstract][Full Text] [Related]
5. Pre-analytical conditions and implementation of quality control steps in liquid biopsy analysis.
Ntzifa A; Lianidou E
Crit Rev Clin Lab Sci; 2023 Dec; 60(8):573-594. PubMed ID: 37518938
[TBL] [Abstract][Full Text] [Related]
6. [Liquid Biopsy: Challenges and Possibilities Regarding Its Clinical Application.].
Furuta K
Rinsho Byori; 2016 May; 64(4):394-399. PubMed ID: 29182805
[TBL] [Abstract][Full Text] [Related]
7. Next-Generation Novel Noninvasive Cancer Molecular Diagnostics Platforms Beyond Tissues.
Wu X; Zhu L; Ma PC
Am Soc Clin Oncol Educ Book; 2018 May; 38(38):964-977. PubMed ID: 30231325
[TBL] [Abstract][Full Text] [Related]
8. International differences in companion diagnostic approvals: how are we able to manage the differences?
Shimazawa R; Ikeda M
Expert Rev Mol Diagn; 2015 Feb; 15(2):157-9. PubMed ID: 25308218
[TBL] [Abstract][Full Text] [Related]
9. Focused size selection of cell-free DNA samples for liquid biopsy applications that rely on next-generation sequencing.
Raymond CK
Biotechniques; 2019 Oct; 67(4):188-191. PubMed ID: 31502470
[TBL] [Abstract][Full Text] [Related]
10. Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.
Levy B; Hu ZI; Cordova KN; Close S; Lee K; Becker D
Oncologist; 2016 Sep; 21(9):1121-30. PubMed ID: 27388233
[TBL] [Abstract][Full Text] [Related]
11. Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review).
Finotti A; Allegretti M; Gasparello J; Giacomini P; Spandidos DA; Spoto G; Gambari R
Int J Oncol; 2018 Oct; 53(4):1395-1434. PubMed ID: 30085333
[TBL] [Abstract][Full Text] [Related]
12. Regulatory approval pathways for molecular diagnostic technology.
Liotta LA; Petricoin EF
Methods Mol Biol; 2012; 823():409-20. PubMed ID: 22081361
[TBL] [Abstract][Full Text] [Related]
13. Challenges and opportunities for next-generation sequencing in companion diagnostics.
Lin E; Chien J; Ong FS; Fan JB
Expert Rev Mol Diagn; 2015 Feb; 15(2):193-209. PubMed ID: 25249308
[TBL] [Abstract][Full Text] [Related]
14. A New Era in Liquid Biopsy: From Genotype to Phenotype.
Kelley SO; Pantel K
Clin Chem; 2020 Jan; 66(1):89-96. PubMed ID: 31811003
[TBL] [Abstract][Full Text] [Related]
15. [Innovations in personalized medicine : Molecular characterization of liquid biopsy-fake or fact?].
Theil G; Fornara P
Urologe A; 2018 Sep; 57(9):1069-1074. PubMed ID: 29971453
[TBL] [Abstract][Full Text] [Related]
16. Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test.
Vasseur D; Sassi H; Bayle A; Tagliamento M; Besse B; Marzac C; Arbab A; Auger N; Cotteret S; Aldea M; Blanc-Durand F; Géraud A; Gazzah A; Loriot Y; Hollebecque A; Martín-Romano P; Ngo-Camus M; Nicotra C; Ponce S; Sakkal M; Caron O; Smolenschi C; Micol JB; Italiano A; Rouleau E; Lacroix L
Cells; 2022 Jun; 11(12):. PubMed ID: 35741030
[TBL] [Abstract][Full Text] [Related]
17. Liquid Biopsy: General Concepts.
Poulet G; Massias J; Taly V
Acta Cytol; 2019; 63(6):449-455. PubMed ID: 31091522
[TBL] [Abstract][Full Text] [Related]
18. Incorporating liquid biopsies into treatment decision-making: obstacles and possibilities.
Beije N; Martens JWM; Sleijfer S
Drug Discov Today; 2019 Sep; 24(9):1715-1719. PubMed ID: 31170504
[TBL] [Abstract][Full Text] [Related]
19. Cell free circulating tumor nucleic acids, a revolution in personalized cancer medicine.
Kerachian MA; Poudineh A; Thiery JP
Crit Rev Oncol Hematol; 2019 Dec; 144():102827. PubMed ID: 31715326
[TBL] [Abstract][Full Text] [Related]
20. Liquid Biopsy Promotes Non-Small Cell Lung Cancer Precision Therapy.
Lu J; Han B
Technol Cancer Res Treat; 2018 Jan; 17():1533033818801809. PubMed ID: 30244652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
